BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

BridgeBio Pharma has rallied 29% over the past three months, fueled by accelerating sales of Attruby, its FDA-approved treatment for a rare heart condition. The drug generated $222 million in second-quarter revenue, more than tripling year-over-year results.

Wall Street remains bullish despite the company's lack of profitability. Sixteen of 17 analysts covering BBIO rate the stock a buy, citing momentum from Attruby and a pipeline of three late-stage candidates currently under FDA review. The strong analyst consensus suggests upside from current levels, as the commercial ramp of Attruby continues and regulatory catalysts approach.

The Q2 sales figure marks a sharp inflection for BBIO, validating the market opportunity for rare-disease treatments and the company's ability to scale commercialization. With multiple shots on goal in late-stage development, the stock is positioned for further catalysts as FDA decisions near.